A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

PHASE4CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

November 11, 2009

Primary Completion Date

June 6, 2017

Study Completion Date

July 1, 2017

Conditions
Renal Cell Carcinoma
Interventions
DRUG

RAD001

Trial Locations (22)

1007

Novartis Investigative Site, Tunis

2080

Novartis Investigative Site, Aryanah

2193

Novartis Investigative Site, Parktown

4000

Novartis Investigative Site, Sousse

4001

Novartis Investigative Site, Durban

7500

Novartis Investigative Site, Cape Town

7925

Novartis Investigative Site, Cape Town

10400

Novartis Investigative Site, Bangkok

11211

Novartis Investigative Site, Riyadh

11941

Novartis Investigative Site, Amman

21131

Novartis Investigative Site, Alexandria

50200

Novartis Investigative Site, Chiang Mai

90110

Novartis Investigative Site, Songkhla

115478

Novartis Investigative Site, Moscow

166830

Novartis Investigative Site, El Achrafiyé

411013

Novartis Investigative Site, Pune

443031

Novartis Investigative Site, Samara

016000

Novartis Investigative Site, Algiers

Unknown

Novartis Investigative Site, Oran

Novartis Investigative Site, Al Mansurah

Novartis Investigative Site, Cairo

452 008

Novartis Investigative Site, Indore

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY